<!DOCTYPE article
 PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="preprint"><?all-math-mml yes?><?use-mml?><?origin ukpmcpa?><front><journal-meta><journal-id journal-id-type="nlm-ta">bioRxiv</journal-id><journal-title-group><journal-title>bioRxiv : the preprint server for biology</journal-title></journal-title-group><issn pub-type="ppub"/></journal-meta><article-meta><article-id pub-id-type="manuscript">EMS140404</article-id><article-id pub-id-type="doi">10.1101/2021.11.28.470226</article-id><article-id pub-id-type="archive">PPR426176</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group><subj-group subj-group-type="europepmc-category"><subject>Covid-19</subject></subj-group></article-categories><title-group><article-title>Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir (PF-07321332)</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4184-7024</contrib-id><name><surname>Ullrich</surname><given-names>Sven</given-names></name></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3078-5895</contrib-id><name><surname>Ekanayake</surname><given-names>Kasuni B.</given-names></name></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0563-0146</contrib-id><name><surname>Otting</surname><given-names>Gottfried</given-names></name></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3704-2699</contrib-id><name><surname>Nitsche</surname><given-names>Christoph</given-names></name><xref ref-type="corresp" rid="CR1">*</xref></contrib><aff id="A1">Research School of Chemistry, Australian National University, Canberra, ACT 2601, Australia</aff></contrib-group><author-notes><corresp id="CR1">
               <label>*</label>
               <email>christoph.nitsche@anu.edu.au</email>
            </corresp></author-notes><pub-date pub-type="nihms-submitted"><day>01</day><month>12</month><year>2021</year></pub-date><pub-date pub-type="preprint"><day>30</day><month>11</month><year>2021</year></pub-date><permissions><ali:free_to_read/><license><ali:license_ref>https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">CC BY-NC-ND 4.0 International license</ext-link>.</license-p></license></permissions><abstract><p id="P1">The COVID-19 pandemic continues to be a public health threat. Multiple mutations in the spike protein of emerging variants of SARS-CoV-2 appear to impact on the effectiveness of available vaccines. Specific antiviral agents are keenly anticipated but their efficacy may also be compromised in emerging variants. One of the most attractive coronaviral drug targets is the main protease (M<sup>pro</sup>). A promising M<sup>pro</sup> inhibitor of clinical relevance is the peptidomimetic nirmatrelvir (PF-07321332). We expressed M<sup>pro</sup> of six SARS-CoV-2 lineages (C.37 Lambda, B.1.1.318, B.1.2, B.1.351 Beta, B.1.1.529 Omicron, P.2 Zeta), each of which carries a strongly prevalent missense mutation (G15S, T21I, L89F, K90R, P132H, L205V). Enzyme kinetics showed that these M<sup>pro</sup> variants are similarly catalytically competent as the wildtype. We show that nirmatrelvir has similar potency against the variants as against the wildtype. Our <italic>in vitro</italic> data suggest that the efficacy of the specific M<sup>pro</sup> inhibitor nirmatrelvir is not compromised in current COVID-19 variants.</p></abstract><abstract abstract-type="graphical"><p id="P2">
               <fig id="F3" position="anchor"><label>Graphical Abstract</label><graphic xlink:href="EMS140404-f003"/></fig>
            </p></abstract><kwd-group><kwd>SARS-CoV-2</kwd><kwd>main protease</kwd><kwd>variants</kwd><kwd>nirmatrelvir</kwd><kwd>inhibitors</kwd></kwd-group></article-meta></front><body><p id="P3">Since its emergence in late 2019,<sup><xref ref-type="bibr" rid="R1">1</xref></sup> COVID-19 has significantly impacted on societies worldwide.<sup><xref ref-type="bibr" rid="R2">2</xref></sup> More than 5 million deaths have been attributed to COVID-19, with the number of confirmed SARS-CoV-2 infections surpassing 275 million.<sup><xref ref-type="bibr" rid="R3">3</xref></sup> The outbreak of SARS-CoV-2 prompted multiple successful vaccine development campaigns.<sup><xref ref-type="bibr" rid="R4">4</xref></sup> Currently approved vaccines, such as viral vector or mRNA vaccines, successfully limited the pandemic’s impact on global health.<sup><xref ref-type="bibr" rid="R5">5</xref>, <xref ref-type="bibr" rid="R6">6</xref></sup> Most COVID-19 vaccines function by stimulating an immune response against the SARS-CoV-2 spike protein (S)<sup><xref ref-type="bibr" rid="R7">7</xref>–<xref ref-type="bibr" rid="R9">9</xref></sup> but, as the spike gene has gathered pronounced genetic variability,<sup><xref ref-type="bibr" rid="R10">10</xref>, <xref ref-type="bibr" rid="R11">11</xref></sup> it is a concern if the effectiveness of existing vaccines are affected by variants of SARS-CoV-2.<sup><xref ref-type="bibr" rid="R5">5</xref>, <xref ref-type="bibr" rid="R6">6</xref>, <xref ref-type="bibr" rid="R10">10</xref>, <xref ref-type="bibr" rid="R12">12</xref></sup> At the time of writing, the World Health Organization (WHO) lists five variants of concern (VOC; Alpha, Beta, Gamma, Delta, Omicron) and two variants of interest (VOI; Lambda, Mu).<sup><xref ref-type="bibr" rid="R13">13</xref></sup> A possible reformulation of the vaccines adjusted to currently circulating lineages of SARS-CoV-2 is being investigated.<sup><xref ref-type="bibr" rid="R14">14</xref>–<xref ref-type="bibr" rid="R16">16</xref></sup> It is clear that the deployment of vaccines remains the best public health measure to control the spread of SARS-CoV-2 and the severe health effects of COVID-19.<sup><xref ref-type="bibr" rid="R17">17</xref>, <xref ref-type="bibr" rid="R18">18</xref></sup>
      </p><p id="P4">Complementary to preventive vaccines, antiviral drugs are urgently needed to combat COVID-19.<sup><xref ref-type="bibr" rid="R19">19</xref></sup> Since the discovery of SARS-CoV-1 in 2003,<sup><xref ref-type="bibr" rid="R20">20</xref></sup> several coronaviral drug targets have been identified,<sup><xref ref-type="bibr" rid="R21">21</xref></sup> including the RNA-dependent RNA polymerase (RdRp, nsp12),<sup><xref ref-type="bibr" rid="R22">22</xref></sup> the helicase (nsp13),<sup><xref ref-type="bibr" rid="R23">23</xref></sup> the papain-like protease (PL<sup>pro</sup>, part of nsp3),<sup><xref ref-type="bibr" rid="R24">24</xref></sup> and the main protease (M<sup>pro</sup>, 3CL<sup>pro</sup>, nsp5).<sup><xref ref-type="bibr" rid="R25">25</xref></sup> Despite this, treatment options for COVID-19 are limited. Only very recently, the orally active drugs molnupiravir (MK-4482, EIDD-2801, Lagevrio™) and nirmatrelvir (PF-07321332, Paxlovid™ as combination drug with ritonavir as booster) were approved for emergency use in the United Kingdom and the United States in November and December 2021. Molnupiravir targets RdRp by acting as a nucleoside analogue prodrug, but was originally developed against different RNA viruses.<sup><xref ref-type="bibr" rid="R26">26</xref></sup> Nirmatrelvir is an orally available peptidomimetic targeting Mpro, employing a nitrile warhead to covalently bind the catalytic cysteine residue in the active site of the protease (<xref ref-type="fig" rid="F2">Figure 2a</xref>).<sup><xref ref-type="bibr" rid="R27">27</xref></sup>
      </p><p id="P5">SARS-CoV-2 M<sup>pro</sup> is a homodimeric cysteine protease, which processes the majority of the viral polyproteins pp1a and pp1ab encoded by the ORF1a/b gene.<sup><xref ref-type="bibr" rid="R25">25</xref>, <xref ref-type="bibr" rid="R28">28</xref></sup> Inhibition of M<sup>pro</sup> thus ultimately hinders the assembly of the replication and transcription complexes (RTCs).<sup><xref ref-type="bibr" rid="R25">25</xref>, <xref ref-type="bibr" rid="R29">29</xref></sup> The protease has a distinct recognition motif, with – in the Schechter-Berger notation<sup><xref ref-type="bibr" rid="R30">30</xref></sup> – preference for leucine in P<sub>2</sub> and especially strong preference for glutamine in P<sub>1</sub>.<sup><xref ref-type="bibr" rid="R25">25</xref>, <xref ref-type="bibr" rid="R31">31</xref></sup> Human host proteases have different substrate specificities and it is therefore anticipated that selective inhibitors have limited off-target effects.<sup><xref ref-type="bibr" rid="R25">25</xref></sup>
      </p><p id="P6">Previous research on SARS-CoV-1 M<sup>pro</sup> (which is 96% identical in amino acid sequence to SARS-CoV-2 M<sup>pro</sup>)<sup><xref ref-type="bibr" rid="R25">25</xref></sup> demonstrated that missense point mutations can influence protease activity. Mutants have been identified with slightly enhanced (Ser284, Thr285, Ile286)<sup><xref ref-type="bibr" rid="R32">32</xref>, <xref ref-type="bibr" rid="R33">33</xref></sup> and slightly or severely reduced catalytic activity (Gly11, Asn28, Ser139, Phe140, Glu166, Asn214, Arg298).<sup><xref ref-type="bibr" rid="R32">32</xref>, <xref ref-type="bibr" rid="R34">34</xref>–<xref ref-type="bibr" rid="R38">38</xref></sup> Specifically the R298A mutation has become a tool to study the protease in its monomeric form, since it inactivates the protease by disrupting the M<sup>pro</sup> dimer.<sup><xref ref-type="bibr" rid="R35">35</xref></sup> The present study assesses the M<sup>pro</sup> mutants of emerging SARS-CoV-2 lineages. We analysed the most widespread amino acid substitutions in SARS-CoV-2 M<sup>pro</sup>, characterized them by enzyme kinetics and assessed their susceptibility to inhibition by nirmatrelvir.</p><p id="P7">Utilizing the <ext-link ext-link-type="uri" xlink:href="https://outbreak.info/">Outbreak.info</ext-link> database by Scripps Research,<sup><xref ref-type="bibr" rid="R39">39</xref></sup> which partially operates with data provided by the GISAID Initiative,<sup><xref ref-type="bibr" rid="R40">40</xref></sup> we performed an analysis of the genomes of SARS-CoV-2 lineages, including the VOC and VOI. The WIV04 sequence (EPI_ISL_402124)<sup><xref ref-type="bibr" rid="R41">41</xref></sup> acted as wildtype (WT) reference genome. Lineage comparison<sup><xref ref-type="bibr" rid="R42">42</xref></sup> of VOCs and VOIs revealed two missense mutations in the M<sup>pro</sup> section of the ORF1a/b gene with &gt;20% frequency of occurrance. The mutations are G15S, which is &gt;85% prevalent<sup><xref ref-type="bibr" rid="R43">43</xref></sup> in the Lambda VOI (or C.37, using PANGO nomenclature)<sup><xref ref-type="bibr" rid="R44">44</xref></sup>, K90R, which is &gt;95% prevalent<sup><xref ref-type="bibr" rid="R45">45</xref></sup> in the Beta VOC (B.1.351) and P132H, which is &gt;95% prevalent<sup><xref ref-type="bibr" rid="R46">46</xref></sup> in the Omicron VOC (B.1.1.529). The Delta VOC (B.1.617.2), which was the dominant lineage for most of the second half of 2021,<sup><xref ref-type="bibr" rid="R47">47</xref>, <xref ref-type="bibr" rid="R48">48</xref></sup> did not display any particularly prevalent (&gt;20%)<sup><xref ref-type="bibr" rid="R42">42</xref></sup> missense mutations within the M<sup>pro</sup> part of ORF1a/b, implying that its M<sup>pro</sup> is identical to that of the WT. We additionally chose to investigate three additional abundant M<sup>pro</sup> mutations to cover a larger variety of lineages: T21I, which is &gt;90% prevalent<sup><xref ref-type="bibr" rid="R49">49</xref></sup> in B.1.1.318, a WHO variant formerly under monitoring (VUM),<sup><xref ref-type="bibr" rid="R13">13</xref></sup> L89F, which is &gt;95% prevalent<sup><xref ref-type="bibr" rid="R50">50</xref></sup> in the B.1.2 lineage, and L205V, which is &gt;95% prevalent<sup><xref ref-type="bibr" rid="R51">51</xref></sup> in the former VOI Zeta (P.2) (<xref ref-type="fig" rid="F1">Figure 1b</xref>). Hence, we selected the six mutations G15S, T21I, L89F, K90R, P132H and L205V for further investigations.</p><p id="P8">X-ray crystal structures of WT SARS-CoV-2 M<sup>pro</sup> (e.g. PDB: 6LU7)<sup><xref ref-type="bibr" rid="R52">52</xref></sup> indicate that the residues G15, T21, K90 and P132 are solvent-exposed, while the hydrophobic residues L89 and L205 are buried within the protease. Except for T21I and P132H, the mutations introduce no major changes in the chemical character of the side-chains, as indicated by low – or in the case of T21I and P132H moderate – values of Miyata’s distances.<sup><xref ref-type="bibr" rid="R53">53</xref></sup> The mutations G15S, T21I, L89F and K90R are located in domain I, while the mutations P132H and L205V are in domains II and III, respectively (<xref ref-type="fig" rid="F1">Figure 1a</xref>).<sup><xref ref-type="bibr" rid="R25">25</xref></sup>
      </p><p id="P9">WT SARS-CoV-2 M<sup>pro</sup> and the mutants G15S, T21I, L89F, K90R, P132H and L205V were expressed in <italic>E. coli</italic> and purified. An established Förster resonance electron transfer (FRET) <italic>in vitro</italic> assay of M<sup>pro</sup> activity<sup><xref ref-type="bibr" rid="R54">54</xref></sup> was employed to determine initial velocities of the proteolytic activity at various substrate concentrations. The data confirmed that all mutants are enzymatically active, which was expected<sup><xref ref-type="bibr" rid="R25">25</xref>, <xref ref-type="bibr" rid="R55">55</xref></sup> as a dysfunctional M<sup>pro</sup> would prevent replication of SARS-CoV-2. The seven M<sup>pro</sup> variants exhibited turnover numbers (<italic>k</italic>
         <sub>cat</sub>) between 0.54 and 1.03 s<sup>-1</sup>, and Michaelis constants (<italic>K</italic>
         <sub>m</sub>) ranging from 37 to 67 μM (<xref ref-type="supplementary-material" rid="SD1">Table S1</xref>). The catalytic efficiencies (<italic>k</italic>
         <sub>cat</sub>/<italic>K</italic>
         <sub>m</sub>) calculated for the mutants (0.009 to 0.023 s<sup>-1</sup>μM<sup>-1</sup>) are similar to that of WT M<sup>pro</sup> (0.016 s<sup>-1</sup>μM<sup>-1</sup>), confirming that all M<sup>pro</sup> variants are equally competent with regard to their proteolytic activities (<xref ref-type="fig" rid="F1">Figure 1c</xref>, <xref ref-type="supplementary-material" rid="SD1">Table S1</xref>).</p><p id="P10">Following the kinetic analysis of the SARS-CoV-2 M<sup>pro</sup> variants, the clinical candidate nirmatrelvir (also known as PF-07321332 ; <xref ref-type="fig" rid="F2">Figure 2a</xref>) was used to assess the potential impact of M<sup>pro</sup> mutations on the drug’s efficacy. The inhibition constant (<italic>K</italic>
         <sub>i</sub>) of nirmatrelvir against SARS-CoV-2 WT M<sup>pro</sup> has been reported to be 3.1 nM.<sup><xref ref-type="bibr" rid="R27">27</xref></sup> Our FRET assay confirmed that nirmatrelvir inhibits the activity of M<sup>pro</sup> variants at nanomolar compound concentrations. Furthermore, the extent of inhibition was similar across the different protease variants, with 5 nM compound displaying inhibition below 50%, 20 nM showing inhibition over 50% and 100 nM fully inhibiting the enzymatic activity of all mutants and the WT (<xref ref-type="fig" rid="F2">Figure 2b</xref>).</p><p id="P11">In summary, we identified the currently most prevalent M<sup>pro</sup> variants (G15S, T21I, L89F, K90R, P132H, L205V) in different lineages of SARS-CoV-2 (C.37 Lambda, B.1.1.318, B.1.2, B.1.351 Beta, B.1.1.529 Omicron, P.2 Zeta) and found that in a biochemical assay they are similarly catalytically competent as the wildtype. In addition, we confirmed that nirmatrelvir maintains effective inhibition of all these M<sup>pro</sup> variants <italic>in vitro.</italic> This gives hope that nirmatrelvir and potentially other specific SARS-CoV-2 M<sup>pro</sup> inhibitors would presently not be affected negatively by these virus variants. It must be noted, however, that widespread use of M<sup>pro</sup> inhibitors may challenge SARS-CoV-2 to develop M<sup>pro</sup> mutations that overcome these inhibitors, as previously experienced for, e.g., HIV protease inhibitors.<sup><xref ref-type="bibr" rid="R56">56</xref></sup> Despite these challenges, protease inhibitors have revolutionized antiviral treatment for viral infectious diseases, including HIV and HCV.<sup><xref ref-type="bibr" rid="R57">57</xref></sup> It can thus be expected that M<sup>pro</sup> inhibitors will have a similar impact on the future development of the COVID-19 pandemic.</p><sec sec-type="supplementary-material" id="SM"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SD1"><label>Supporting Information</label><media xlink:href="EMS140404-supplement-Supporting_Information.pdf" mimetype="application" mime-subtype="pdf" id="d22aAdJbB" position="anchor"/></supplementary-material></sec></body><back><ack id="S1"><title>Acknowledgements</title><p>C.N. thanks the Australian Research Council (ARC) for a Discovery Early Career Research Award (DE190100015) and Discovery Project funding (DP200100348). G.O. thanks the ARC for a Laureate Fellowship (FL170100019) and acknowledges support by the ARC Centre of Excellence for Innovations in Peptide &amp; Protein Science (CE200100012). This study was supported by a RAMR (MAWA) grant awarded to S.U. and C.N.</p></ack><fn-group><fn id="FN1" fn-type="conflict"><p id="P12">
               <bold>Competing Interest Declaration</bold>
            </p><p id="P13">The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</p></fn></fn-group><ref-list><ref id="R1"><label>(1)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>N</given-names></name><name><surname>Zhang</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>B</given-names></name><name><surname>Song</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>B</given-names></name><name><surname>Shi</surname><given-names>W</given-names></name><name><surname>Lu</surname><given-names>R</given-names></name><etal/></person-group><article-title>A novel coronavirus from patients with pneumonia in China, 2019</article-title><source>N Engl J Med</source><year>2020</year><volume>382</volume><issue>8</issue><fpage>727</fpage><lpage>733</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2001017</pub-id></element-citation></ref><ref id="R2"><label>(2)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hiscott</surname><given-names>J</given-names></name><name><surname>Alexandridi</surname><given-names>M</given-names></name><name><surname>Muscolini</surname><given-names>M</given-names></name><name><surname>Tassone</surname><given-names>E</given-names></name><name><surname>Palermo</surname><given-names>E</given-names></name><name><surname>Soultsioti</surname><given-names>M</given-names></name><name><surname>Zevini</surname><given-names>A</given-names></name></person-group><article-title>The global impact of the coronavirus pandemic</article-title><source>Cytokine Growth Factor Rev</source><year>2020</year><volume>53</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.cytogfr.2020.05.010</pub-id></element-citation></ref><ref id="R3"><label>(3)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>E</given-names></name><name><surname>Du</surname><given-names>H</given-names></name><name><surname>Gardner</surname><given-names>L</given-names></name></person-group><article-title>An interactive web-based dashboard to track COVID-19 in real time</article-title><source>Lancet Infect Dis</source><year>2020</year><volume>20</volume><issue>5</issue><fpage>533</fpage><lpage>534</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(20)30120-1</pub-id></element-citation></ref><ref id="R4"><label>(4)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Zeng</surname><given-names>H</given-names></name><name><surname>Gu</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Zheng</surname><given-names>L</given-names></name><name><surname>Zou</surname><given-names>Q</given-names></name></person-group><article-title>Progress and prospects on vaccine development against SARS-CoV-2</article-title><source>Vaccines</source><year>2020</year><volume>8</volume><issue>2</issue><elocation-id>153</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines8020153</pub-id></element-citation></ref><ref id="R5"><label>(5)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subbarao</surname><given-names>K</given-names></name></person-group><article-title>The success of SARS-CoV-2 vaccines and challenges ahead</article-title><source>Cell Host Microbe</source><year>2021</year><volume>29</volume><issue>7</issue><fpage>1111</fpage><lpage>1123</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2021.06.016</pub-id></element-citation></ref><ref id="R6"><label>(6)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tregoning</surname><given-names>JS</given-names></name><name><surname>Flight</surname><given-names>KE</given-names></name><name><surname>Higham</surname><given-names>SL</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Pierce</surname><given-names>BF</given-names></name></person-group><article-title>Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape</article-title><source>Nat Rev Immunol</source><year>2021</year><volume>21</volume><issue>10</issue><fpage>626</fpage><lpage>636</lpage><pub-id pub-id-type="doi">10.1038/s41577-021-00592-1</pub-id></element-citation></ref><ref id="R7"><label>(7)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le</surname><given-names>TT</given-names></name><name><surname>Cramer</surname><given-names>JP</given-names></name><name><surname>Chen</surname><given-names>R</given-names></name><name><surname>Mayhew</surname><given-names>S</given-names></name></person-group><article-title>Evolution of the COVID-19 vaccine development landscape</article-title><source>Nat Rev Drug Discov</source><year>2020</year><volume>19</volume><issue>10</issue><fpage>667</fpage><lpage>668</lpage><pub-id pub-id-type="doi">10.1038/d41573-020-00151-8</pub-id></element-citation></ref><ref id="R8"><label>(8)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teijaro</surname><given-names>JR</given-names></name><name><surname>Farber</surname><given-names>DL</given-names></name></person-group><article-title>COVID-19 vaccines: modes of immune activation and future challenges</article-title><source>Nat Rev Immunol</source><year>2021</year><volume>21</volume><issue>4</issue><fpage>195</fpage><lpage>197</lpage><pub-id pub-id-type="doi">10.1038/s41577-021-00526-x</pub-id></element-citation></ref><ref id="R9"><label>(9)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dupont</surname><given-names>L</given-names></name><name><surname>Snell</surname><given-names>LB</given-names></name><name><surname>Graham</surname><given-names>C</given-names></name><name><surname>Seow</surname><given-names>J</given-names></name><name><surname>Merrick</surname><given-names>B</given-names></name><name><surname>Lechmere</surname><given-names>T</given-names></name><name><surname>Maguire</surname><given-names>TJA</given-names></name><name><surname>Hallett</surname><given-names>SR</given-names></name><name><surname>Pickering</surname><given-names>S</given-names></name><name><surname>Charalampous</surname><given-names>T</given-names></name><etal/></person-group><article-title>Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern</article-title><source>Nat Microbiol</source><year>2021</year><volume>6</volume><issue>11</issue><fpage>1433</fpage><lpage>1442</lpage><pub-id pub-id-type="doi">10.1038/s41564-021-00974-0</pub-id></element-citation></ref><ref id="R10"><label>(10)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tao</surname><given-names>K</given-names></name><name><surname>Tzou</surname><given-names>PL</given-names></name><name><surname>Nouhin</surname><given-names>J</given-names></name><name><surname>Gupta</surname><given-names>RK</given-names></name><name><surname>de Oliveira</surname><given-names>T</given-names></name><name><surname>Kosakovsky Pond</surname><given-names>SL</given-names></name><name><surname>Fera</surname><given-names>D</given-names></name><name><surname>Shafer</surname><given-names>RW</given-names></name></person-group><article-title>The biological and clinical significance of emerging SARS-CoV-2 variants</article-title><source>Nat Rev Genet</source><year>2021</year><volume>22</volume><issue>12</issue><fpage>757</fpage><lpage>773</lpage><pub-id pub-id-type="doi">10.1038/s41576-021-00408-x</pub-id></element-citation></ref><ref id="R11"><label>(11)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harvey</surname><given-names>WT</given-names></name><name><surname>Carabelli</surname><given-names>AM</given-names></name><name><surname>Jackson</surname><given-names>B</given-names></name><name><surname>Gupta</surname><given-names>RK</given-names></name><name><surname>Thomson</surname><given-names>EC</given-names></name><name><surname>Harrison</surname><given-names>EM</given-names></name><name><surname>Ludden</surname><given-names>C</given-names></name><name><surname>Reeve</surname><given-names>R</given-names></name><name><surname>Rambaut</surname><given-names>A</given-names></name><name><surname>Peacock</surname><given-names>SJ</given-names></name><etal/></person-group><article-title>SARS-CoV-2 variants, spike mutations and immune escape</article-title><source>Nat Rev Microbiol</source><year>2021</year><volume>19</volume><issue>7</issue><fpage>409</fpage><lpage>424</lpage><pub-id pub-id-type="doi">10.1038/s41579-021-00573-0</pub-id></element-citation></ref><ref id="R12"><label>(12)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tatsi</surname><given-names>E-B</given-names></name><name><surname>Filippatos</surname><given-names>F</given-names></name><name><surname>Michos</surname><given-names>A</given-names></name></person-group><article-title>SARS-CoV-2 variants and effectiveness of vaccines: a review of current evidence</article-title><source>Epidemiol Infect</source><year>2021</year><fpage>1</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1017/s0950268821002430</pub-id></element-citation></ref><ref id="R13"><label>(13)</label><element-citation publication-type="web"><collab>World Health Organization</collab><source>Tracking SARS-CoV-2 variants</source><year>2021</year><date-in-citation>accessed 18 December 2021</date-in-citation><comment><ext-link ext-link-type="uri" xlink:href="https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/">https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/</ext-link></comment></element-citation></ref><ref id="R14"><label>(14)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prévost</surname><given-names>J</given-names></name><name><surname>Finzi</surname><given-names>A</given-names></name></person-group><article-title>The great escape? SARS-CoV-2 variants evading neutralizing responses</article-title><source>Cell Host Microbe</source><year>2021</year><volume>29</volume><issue>3</issue><fpage>322</fpage><lpage>324</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2021.02.010</pub-id></element-citation></ref><ref id="R15"><label>(15)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Zyoud</surname><given-names>W</given-names></name><name><surname>Haddad</surname><given-names>H</given-names></name></person-group><article-title>Dynamics prediction of emerging notable spike protein mutations in SARS-CoV-2 implies a need for updated vaccines</article-title><source>Biochimie</source><year>2021</year><volume>191</volume><fpage>91</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1016/j.biochi.2021.08.011</pub-id></element-citation></ref><ref id="R16"><label>(16)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cevik</surname><given-names>M</given-names></name><name><surname>Grubaugh</surname><given-names>ND</given-names></name><name><surname>Iwasaki</surname><given-names>A</given-names></name><name><surname>Openshaw</surname><given-names>P</given-names></name></person-group><article-title>COVID-19 vaccines: keeping pace with SARS-CoV-2 variants</article-title><source>Cell</source><year>2021</year><volume>184</volume><issue>20</issue><fpage>5077</fpage><lpage>5081</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2021.09.010</pub-id></element-citation></ref><ref id="R17"><label>(17)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grubaugh</surname><given-names>ND</given-names></name><name><surname>Hodcroft</surname><given-names>EB</given-names></name><name><surname>Fauver</surname><given-names>JR</given-names></name><name><surname>Phelan</surname><given-names>AL</given-names></name><name><surname>Cevik</surname><given-names>M</given-names></name></person-group><article-title>Public health actions to control new SARS-CoV-2 variants</article-title><source>Cell</source><year>2021</year><volume>184</volume><issue>5</issue><fpage>1127</fpage><lpage>1132</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2021.01.044</pub-id></element-citation></ref><ref id="R18"><label>(18)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Viana</surname><given-names>J</given-names></name><name><surname>van Dorp</surname><given-names>CH</given-names></name><name><surname>Nunes</surname><given-names>A</given-names></name><name><surname>Gomes</surname><given-names>MC</given-names></name><name><surname>van Boven</surname><given-names>M</given-names></name><name><surname>Kretzschmar</surname><given-names>ME</given-names></name><name><surname>Veldhoen</surname><given-names>M</given-names></name><name><surname>Rozhnova</surname><given-names>G</given-names></name></person-group><article-title>Controlling the pandemic during the SARS-CoV-2 vaccination rollout</article-title><source>Nat Commun</source><year>2021</year><volume>12</volume><issue>1</issue><elocation-id>3674</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-021-23938-8</pub-id></element-citation></ref><ref id="R19"><label>(19)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hobman</surname><given-names>TC</given-names></name><name><surname>Murgolo</surname><given-names>N</given-names></name><name><surname>Therien</surname><given-names>AG</given-names></name><name><surname>Howell</surname><given-names>B</given-names></name><name><surname>Klein</surname><given-names>D</given-names></name><name><surname>Koeplinger</surname><given-names>K</given-names></name><name><surname>Lieberman</surname><given-names>LA</given-names></name><name><surname>Adam</surname><given-names>GC</given-names></name><name><surname>Flynn</surname><given-names>J</given-names></name><name><surname>McKenna</surname><given-names>P</given-names></name><etal/></person-group><article-title>SARS-CoV-2 tropism, entry, replication, and propagation: considerations for drug discovery and development</article-title><source>PLOS Pathog</source><year>2021</year><volume>17</volume><issue>2</issue><elocation-id>e1009225</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1009225</pub-id></element-citation></ref><ref id="R20"><label>(20)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drosten</surname><given-names>C</given-names></name><name><surname>Günther</surname><given-names>S</given-names></name><name><surname>Preiser</surname><given-names>W</given-names></name><name><surname>van der Werf</surname><given-names>S</given-names></name><name><surname>Brodt</surname><given-names>H-R</given-names></name><name><surname>Becker</surname><given-names>S</given-names></name><name><surname>Rabenau</surname><given-names>H</given-names></name><name><surname>Panning</surname><given-names>M</given-names></name><name><surname>Kolesnikova</surname><given-names>L</given-names></name><name><surname>Fouchier</surname><given-names>RAM</given-names></name><etal/></person-group><article-title>Identification of a novel coronavirus in patients with severe acute respiratory syndrome</article-title><source>N Engl J Med</source><year>2003</year><volume>348</volume><issue>20</issue><fpage>1967</fpage><lpage>1976</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa030747</pub-id></element-citation></ref><ref id="R21"><label>(21)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hilgenfeld</surname><given-names>R</given-names></name><name><surname>Peiris</surname><given-names>M</given-names></name></person-group><article-title>From SARS to MERS: 10 years of research on highly pathogenic human coronaviruses</article-title><source>Antivir Res</source><year>2013</year><volume>100</volume><issue>1</issue><fpage>286</fpage><lpage>295</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2013.08.015</pub-id></element-citation></ref><ref id="R22"><label>(22)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>CZ</given-names></name><name><surname>Gorshkov</surname><given-names>K</given-names></name><name><surname>Xu</surname><given-names>M</given-names></name><name><surname>Lo</surname><given-names>DC</given-names></name><name><surname>Zheng</surname><given-names>W</given-names></name></person-group><article-title>RNA-dependent RNA polymerase as a target for COVID-19 drug discovery</article-title><source>SLAS Discov</source><year>2020</year><volume>25</volume><issue>10</issue><fpage>1141</fpage><lpage>1151</lpage><pub-id pub-id-type="doi">10.1177/2472555220942123</pub-id></element-citation></ref><ref id="R23"><label>(23)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spratt</surname><given-names>AN</given-names></name><name><surname>Gallazzi</surname><given-names>F</given-names></name><name><surname>Quinn</surname><given-names>TP</given-names></name><name><surname>Lorson</surname><given-names>CL</given-names></name><name><surname>Sonnerborg</surname><given-names>A</given-names></name><name><surname>Singh</surname><given-names>K</given-names></name></person-group><article-title>Coronavirus helicases: attractive and unique targets of antiviral drug-development and therapeutic patents</article-title><source>Expert Opin Ther Pat</source><year>2021</year><volume>31</volume><issue>4</issue><fpage>339</fpage><lpage>350</lpage><pub-id pub-id-type="doi">10.1080/13543776.2021.1884224</pub-id></element-citation></ref><ref id="R24"><label>(24)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahmoudvand</surname><given-names>S</given-names></name><name><surname>Shokri</surname><given-names>S</given-names></name></person-group><article-title>Interactions between SARS coronavirus 2 papain-like protease and immune system: A potential drug target for the treatment of COVID-19</article-title><source>Scand J Immunol</source><year>2021</year><volume>94</volume><issue>4</issue><elocation-id>e13044</elocation-id><pub-id pub-id-type="doi">10.1111/sji.13044</pub-id></element-citation></ref><ref id="R25"><label>(25)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ullrich</surname><given-names>S</given-names></name><name><surname>Nitsche</surname><given-names>C</given-names></name></person-group><article-title>The SARS-CoV-2 main protease as drug target</article-title><source>Bioorg Med Chem Lett</source><year>2020</year><volume>30</volume><issue>17</issue><elocation-id>127377</elocation-id><pub-id pub-id-type="doi">10.1016/j.bmcl.2020.127377</pub-id></element-citation></ref><ref id="R26"><label>(26)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Painter</surname><given-names>GR</given-names></name><name><surname>Natchus</surname><given-names>MG</given-names></name><name><surname>Cohen</surname><given-names>O</given-names></name><name><surname>Holman</surname><given-names>W</given-names></name><name><surname>Painter</surname><given-names>WP</given-names></name></person-group><article-title>Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19</article-title><source>Curr Opin Virol</source><year>2021</year><volume>50</volume><fpage>17</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1016/j.coviro.2021.06.003</pub-id></element-citation></ref><ref id="R27"><label>(27)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Owen</surname><given-names>DR</given-names></name><name><surname>Allerton</surname><given-names>CMN</given-names></name><name><surname>Anderson</surname><given-names>AS</given-names></name><name><surname>Aschenbrenner</surname><given-names>L</given-names></name><name><surname>Avery</surname><given-names>M</given-names></name><name><surname>Berritt</surname><given-names>S</given-names></name><name><surname>Boras</surname><given-names>B</given-names></name><name><surname>Cardin</surname><given-names>RD</given-names></name><name><surname>Carlo</surname><given-names>A</given-names></name><name><surname>Coffman</surname><given-names>KJ</given-names></name><etal/></person-group><article-title>An oral SARS-CoV-2 M<sup>pro</sup> inhibitor clinical candidate for the treatment of COVID-19</article-title><source>Science</source><year>2021</year><elocation-id>eabl4784</elocation-id><pub-id pub-id-type="doi">10.1126/science.abl4784</pub-id></element-citation></ref><ref id="R28"><label>(28)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>D</given-names></name><name><surname>Lee</surname><given-names>J-Y</given-names></name><name><surname>Yang</surname><given-names>J-S</given-names></name><name><surname>Kim</surname><given-names>JW</given-names></name><name><surname>Kim</surname><given-names>VN</given-names></name><name><surname>Chang</surname><given-names>H</given-names></name></person-group><article-title>The architecture of SARS-CoV-2 transcriptome</article-title><source>Cell</source><year>2020</year><volume>181</volume><issue>4</issue><fpage>914</fpage><lpage>921</lpage><elocation-id>e910</elocation-id><pub-id pub-id-type="doi">10.1016/j.cell.2020.04.011</pub-id></element-citation></ref><ref id="R29"><label>(29)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hartenian</surname><given-names>E</given-names></name><name><surname>Nandakumar</surname><given-names>D</given-names></name><name><surname>Lari</surname><given-names>A</given-names></name><name><surname>Ly</surname><given-names>M</given-names></name><name><surname>Tucker</surname><given-names>JM</given-names></name><name><surname>Glaunsinger</surname><given-names>BA</given-names></name></person-group><article-title>The molecular virology of coronaviruses</article-title><source>J Biol Chem</source><year>2020</year><volume>295</volume><issue>37</issue><fpage>12910</fpage><lpage>12934</lpage><pub-id pub-id-type="doi">10.1074/jbc.REV120.013930</pub-id></element-citation></ref><ref id="R30"><label>(30)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schechter</surname><given-names>I</given-names></name><name><surname>Berger</surname><given-names>A</given-names></name></person-group><article-title>On the size of the active site in proteases. I. Papain</article-title><source>Biochem Biophys Res Commun</source><year>1967</year><volume>27</volume><issue>2</issue><fpage>157</fpage><lpage>162</lpage><pub-id pub-id-type="doi">10.1016/s0006-291x(67)80055-x</pub-id></element-citation></ref><ref id="R31"><label>(31)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rut</surname><given-names>W</given-names></name><name><surname>Groborz</surname><given-names>K</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Zmudzinski</surname><given-names>M</given-names></name><name><surname>Pawlik</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Jochmans</surname><given-names>D</given-names></name><name><surname>Neyts</surname><given-names>J</given-names></name><name><surname>Mlynarski</surname><given-names>W</given-names></name><etal/></person-group><article-title>SARS-CoV-2 Mpro inhibitors and activity-based probes for patient-sample imaging</article-title><source>Nat Chem Biol</source><year>2020</year><volume>17</volume><issue>2</issue><fpage>222</fpage><lpage>228</lpage><pub-id pub-id-type="doi">10.1038/s41589-020-00689-z</pub-id></element-citation></ref><ref id="R32"><label>(32)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>J</given-names></name><name><surname>Song</surname><given-names>J</given-names></name></person-group><article-title>The catalysis of the SARS 3C-like protease is under extensive regulation by its extra domain</article-title><source>FEBS Journal</source><year>2006</year><volume>273</volume><issue>5</issue><fpage>1035</fpage><lpage>1045</lpage><pub-id pub-id-type="doi">10.1111/j.1742-4658.2006.05130.x</pub-id></element-citation></ref><ref id="R33"><label>(33)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fraternali</surname><given-names>F</given-names></name><name><surname>Lim</surname><given-names>L</given-names></name><name><surname>Shi</surname><given-names>J</given-names></name><name><surname>Mu</surname><given-names>Y</given-names></name><name><surname>Song</surname><given-names>J</given-names></name></person-group><article-title>Dynamically-driven enhancement of the catalytic machinery of the SARS 3C-like protease by the S284-T285-I286/A mutations on the extra domain</article-title><source>PLOS One</source><year>2014</year><volume>9</volume><issue>7</issue><elocation-id>e101941</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0101941</pub-id></element-citation></ref><ref id="R34"><label>(34)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Hu</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>K</given-names></name><name><surname>Ding</surname><given-names>J</given-names></name><name><surname>Jiang</surname><given-names>H</given-names></name><name><surname>Shen</surname><given-names>X</given-names></name></person-group><article-title>Mutation of Gly-11 on the dimer interface results in the complete crystallographic dimer dissociation of severe acute respiratory syndrome coronavirus 3C-like protease: crystal structure with molecular dynamics simulations</article-title><source>J Biol Chem</source><year>2008</year><volume>283</volume><issue>1</issue><fpage>554</fpage><lpage>564</lpage><pub-id pub-id-type="doi">10.1074/jbc.M705240200</pub-id></element-citation></ref><ref id="R35"><label>(35)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>J</given-names></name><name><surname>Sivaraman</surname><given-names>J</given-names></name><name><surname>Song</surname><given-names>J</given-names></name></person-group><article-title>Mechanism for controlling the dimer-monomer switch and coupling dimerization to catalysis of the severe acute respiratory syndrome coronavirus 3C-like protease</article-title><source>J Virol</source><year>2008</year><volume>82</volume><issue>9</issue><fpage>4620</fpage><lpage>4629</lpage><pub-id pub-id-type="doi">10.1128/jvi.02680-07</pub-id></element-citation></ref><ref id="R36"><label>(36)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barrila</surname><given-names>J</given-names></name><name><surname>Gabelli</surname><given-names>SB</given-names></name><name><surname>Bacha</surname><given-names>U</given-names></name><name><surname>Amzel</surname><given-names>LM</given-names></name><name><surname>Freire</surname><given-names>E</given-names></name></person-group><article-title>Mutation of Asn28 disrupts the dimerization and enzymatic activity of SARS 3CL<sup>pro</sup></article-title><source>Biochemistry</source><year>2010</year><volume>49</volume><issue>20</issue><fpage>4308</fpage><lpage>4317</lpage><pub-id pub-id-type="doi">10.1021/bi1002585</pub-id></element-citation></ref><ref id="R37"><label>(37)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Ding</surname><given-names>J</given-names></name><name><surname>Jiang</surname><given-names>H</given-names></name><name><surname>Shen</surname><given-names>X</given-names></name></person-group><article-title>Two adjacent mutations on the dimer interface of SARS coronavirus 3C-like protease cause different conformational changes in crystal structure</article-title><source>Virology</source><year>2009</year><volume>388</volume><issue>2</issue><fpage>324</fpage><lpage>334</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2009.03.034</pub-id></element-citation></ref><ref id="R38"><label>(38)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>S-C</given-names></name><name><surname>Chang</surname><given-names>G-G</given-names></name><name><surname>Chou</surname><given-names>C-Y</given-names></name></person-group><article-title>Mutation of Glu-166 blocks the substrate-induced dimerization of SARS coronavirus main protease</article-title><source>Biophys J</source><year>2010</year><volume>98</volume><issue>7</issue><fpage>1327</fpage><lpage>1336</lpage><pub-id pub-id-type="doi">10.1016/j.bpj.2009.12.4272</pub-id></element-citation></ref><ref id="R39"><label>(39)</label><element-citation publication-type="web"><person-group person-group-type="author"><name><surname>Mullen</surname><given-names>JL</given-names></name><name><surname>Tsueng</surname><given-names>G</given-names></name><name><surname>Abdel Latif</surname><given-names>A</given-names></name><name><surname>Alkuzweny</surname><given-names>M</given-names></name><name><surname>Cano</surname><given-names>M</given-names></name><name><surname>Haag</surname><given-names>E</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Zeller</surname><given-names>M</given-names></name><name><surname>Hufbauer</surname><given-names>E</given-names></name><name><surname>Matteson</surname><given-names>N</given-names></name><etal/></person-group><source>Outbreak.info - a standardized, open-source database of COVID-19 resources and epidemiology data</source><year>2020</year><date-in-citation>accessed 7 November 2021</date-in-citation><comment><ext-link ext-link-type="uri" xlink:href="https://outbreak.info/">https://outbreak.info/</ext-link></comment></element-citation></ref><ref id="R40"><label>(40)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elbe</surname><given-names>S</given-names></name><name><surname>Buckland-Merrett</surname><given-names>G</given-names></name></person-group><article-title>Data, disease and diplomacy: GISAID’s innovative contribution to global health</article-title><source>Glob Chall</source><year>2017</year><volume>1</volume><issue>1</issue><fpage>33</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1002/gch2.1018</pub-id></element-citation></ref><ref id="R41"><label>(41)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhukova</surname><given-names>A</given-names></name><name><surname>Blassel</surname><given-names>L</given-names></name><name><surname>Lemoine</surname><given-names>F</given-names></name><name><surname>Morel</surname><given-names>M</given-names></name><name><surname>Voznica</surname><given-names>J</given-names></name><name><surname>Gascuel</surname><given-names>O</given-names></name></person-group><article-title>Origin, evolution and global spread of SARS-CoV-2</article-title><source>C R Biol</source><year>2021</year><volume>344</volume><issue>1</issue><fpage>57</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.5802/crbiol.29</pub-id></element-citation></ref><ref id="R42"><label>(42)</label><element-citation publication-type="web"><person-group person-group-type="author"><name><surname>Abdel Latif</surname><given-names>A</given-names></name><name><surname>Mullen</surname><given-names>JL</given-names></name><name><surname>Alkuzweny</surname><given-names>M</given-names></name><name><surname>Tsueng</surname><given-names>G</given-names></name><name><surname>Cano</surname><given-names>M</given-names></name><name><surname>Haag</surname><given-names>E</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Zeller</surname><given-names>M</given-names></name><name><surname>Hufbauer</surname><given-names>E</given-names></name><name><surname>Matteson</surname><given-names>N</given-names></name><etal/></person-group><source>Outbreak.info - lineage comparison</source><year>2021</year><date-in-citation>accessed 8 November 2021</date-in-citation><comment><ext-link ext-link-type="uri" xlink:href="https://outbreak.info/compare-lineages">https://outbreak.info/compare-lineages</ext-link></comment></element-citation></ref><ref id="R43"><label>(43)</label><element-citation publication-type="report"><person-group person-group-type="author"><name><surname>Abdel Latif</surname><given-names>A</given-names></name><name><surname>Mullen</surname><given-names>JL</given-names></name><name><surname>Alkuzweny</surname><given-names>M</given-names></name><name><surname>Tsueng</surname><given-names>G</given-names></name><name><surname>Cano</surname><given-names>M</given-names></name><name><surname>Haag</surname><given-names>E</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Zeller</surname><given-names>M</given-names></name><name><surname>Hufbauer</surname><given-names>E</given-names></name><name><surname>Matteson</surname><given-names>N</given-names></name><etal/></person-group><source>Outbreak.info - ORF1a:G3278S mutation report</source><year>2021</year><date-in-citation>accessed 8 November 2021</date-in-citation><comment><ext-link ext-link-type="uri" xlink:href="https://outbreak.info/situation-reports?pango&amp;muts=ORF1a%3AG3278S">https://outbreak.info/situation-reports?pango&amp;muts=ORF1a%3AG3278S</ext-link></comment></element-citation></ref><ref id="R44"><label>(44)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rambaut</surname><given-names>A</given-names></name><name><surname>Holmes</surname><given-names>EC</given-names></name><name><surname>O’Toole</surname><given-names>Á</given-names></name><name><surname>Hill</surname><given-names>V</given-names></name><name><surname>McCrone</surname><given-names>JT</given-names></name><name><surname>Ruis</surname><given-names>C</given-names></name><name><surname>du Plessis</surname><given-names>L</given-names></name><name><surname>Pybus</surname><given-names>OG</given-names></name></person-group><article-title>A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology</article-title><source>Nat Microbiol</source><year>2020</year><volume>5</volume><issue>11</issue><fpage>1403</fpage><lpage>1407</lpage><pub-id pub-id-type="doi">10.1038/s41564-020-0770-5</pub-id></element-citation></ref><ref id="R45"><label>(45)</label><element-citation publication-type="report"><person-group person-group-type="author"><name><surname>Abdel Latif</surname><given-names>A</given-names></name><name><surname>Mullen</surname><given-names>JL</given-names></name><name><surname>Alkuzweny</surname><given-names>M</given-names></name><name><surname>Tsueng</surname><given-names>G</given-names></name><name><surname>Cano</surname><given-names>M</given-names></name><name><surname>Haag</surname><given-names>E</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Zeller</surname><given-names>M</given-names></name><name><surname>Hufbauer</surname><given-names>E</given-names></name><name><surname>Matteson</surname><given-names>N</given-names></name><etal/></person-group><source>Outbreak.info - ORF1a:K3353R mutation report</source><year>2021</year><date-in-citation>accessed 8 November 2021</date-in-citation><comment><ext-link ext-link-type="uri" xlink:href="https://outbreak.info/situation-reports?pango&amp;muts=ORF1a%3AK3353R">https://outbreak.info/situation-reports?pango&amp;muts=ORF1a%3AK3353R</ext-link></comment></element-citation></ref><ref id="R46"><label>(46)</label><element-citation publication-type="report"><person-group person-group-type="author"><name><surname>Abdel Latif</surname><given-names>A</given-names></name><name><surname>Mullen</surname><given-names>JL</given-names></name><name><surname>Alkuzweny</surname><given-names>M</given-names></name><name><surname>Tsueng</surname><given-names>G</given-names></name><name><surname>Cano</surname><given-names>M</given-names></name><name><surname>Haag</surname><given-names>E</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Zeller</surname><given-names>M</given-names></name><name><surname>Hufbauer</surname><given-names>E</given-names></name><name><surname>Matteson</surname><given-names>N</given-names></name><etal/></person-group><source>Outbreak.info - ORF1a:P3395H mutation report</source><year>2021</year><date-in-citation>accessed 18 December 2021</date-in-citation><comment><ext-link ext-link-type="uri" xlink:href="https://outbreak.info/situation-reports?pango&amp;muts=ORF1a%3AP3395H">https://outbreak.info/situation-reports?pango&amp;muts=ORF1a%3AP3395H</ext-link></comment></element-citation></ref><ref id="R47"><label>(47)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>X</given-names></name><name><surname>He</surname><given-names>C</given-names></name><name><surname>Hong</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>K</given-names></name><name><surname>Wei</surname><given-names>X</given-names></name></person-group><article-title>The challenges of COVID-19 Delta variant: prevention and vaccine development</article-title><source>MedComm</source><year>2021</year><pub-id pub-id-type="doi">10.1002/mco2.95</pub-id></element-citation></ref><ref id="R48"><label>(48)</label><element-citation publication-type="report"><person-group person-group-type="author"><name><surname>Abdel Latif</surname><given-names>A</given-names></name><name><surname>Mullen</surname><given-names>JL</given-names></name><name><surname>Alkuzweny</surname><given-names>M</given-names></name><name><surname>Tsueng</surname><given-names>G</given-names></name><name><surname>Cano</surname><given-names>M</given-names></name><name><surname>Haag</surname><given-names>E</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Zeller</surname><given-names>M</given-names></name><name><surname>Hufbauer</surname><given-names>E</given-names></name><name><surname>Matteson</surname><given-names>N</given-names></name><etal/></person-group><source>Outbreak.info - variant report by location over time</source><year>2021</year><date-in-citation>accessed 21 December 2021</date-in-citation><comment><ext-link ext-link-type="uri" xlink:href="https://outbreak.info/location-reports?loc">https://outbreak.info/location-reports?loc</ext-link></comment></element-citation></ref><ref id="R49"><label>(49)</label><element-citation publication-type="report"><person-group person-group-type="author"><name><surname>Abdel Latif</surname><given-names>A</given-names></name><name><surname>Mullen</surname><given-names>JL</given-names></name><name><surname>Alkuzweny</surname><given-names>M</given-names></name><name><surname>Tsueng</surname><given-names>G</given-names></name><name><surname>Cano</surname><given-names>M</given-names></name><name><surname>Haag</surname><given-names>E</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Zeller</surname><given-names>M</given-names></name><name><surname>Hufbauer</surname><given-names>E</given-names></name><name><surname>Matteson</surname><given-names>N</given-names></name><etal/></person-group><source>Outbreak.info - ORF1a:T3284I mutation report</source><year>2021</year><date-in-citation>accessed 8 November 2021</date-in-citation><comment><ext-link ext-link-type="uri" xlink:href="https://outbreak.info/situation-reports?pango&amp;muts=ORF1a%3AT3284I">https://outbreak.info/situation-reports?pango&amp;muts=ORF1a%3AT3284I</ext-link></comment></element-citation></ref><ref id="R50"><label>(50)</label><element-citation publication-type="report"><person-group person-group-type="author"><name><surname>Abdel Latif</surname><given-names>A</given-names></name><name><surname>Mullen</surname><given-names>JL</given-names></name><name><surname>Alkuzweny</surname><given-names>M</given-names></name><name><surname>Tsueng</surname><given-names>G</given-names></name><name><surname>Cano</surname><given-names>M</given-names></name><name><surname>Haag</surname><given-names>E</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Zeller</surname><given-names>M</given-names></name><name><surname>Hufbauer</surname><given-names>E</given-names></name><name><surname>Matteson</surname><given-names>N</given-names></name><etal/></person-group><source>Outbreak.info - ORF1a:L3352F mutation report</source><year>2021</year><date-in-citation>accessed 8 November 2021</date-in-citation><comment><ext-link ext-link-type="uri" xlink:href="https://outbreak.info/situation-reports?pango&amp;muts=ORF1a%3AL3352F">https://outbreak.info/situation-reports?pango&amp;muts=ORF1a%3AL3352F</ext-link></comment></element-citation></ref><ref id="R51"><label>(51)</label><element-citation publication-type="report"><person-group person-group-type="author"><name><surname>Abdel Latif</surname><given-names>A</given-names></name><name><surname>Mullen</surname><given-names>JL</given-names></name><name><surname>Alkuzweny</surname><given-names>M</given-names></name><name><surname>Tsueng</surname><given-names>G</given-names></name><name><surname>Cano</surname><given-names>M</given-names></name><name><surname>Haag</surname><given-names>E</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Zeller</surname><given-names>M</given-names></name><name><surname>Hufbauer</surname><given-names>E</given-names></name><name><surname>Matteson</surname><given-names>N</given-names></name><etal/></person-group><source>Outbreak.info - ORF1a:L3468V mutation report</source><year>2021</year><date-in-citation>accessed 8 November 2021</date-in-citation><comment><ext-link ext-link-type="uri" xlink:href="https://outbreak.info/situation-reports?pango&amp;muts=ORF1a%3AL3468V">https://outbreak.info/situation-reports?pango&amp;muts=ORF1a%3AL3468V</ext-link></comment></element-citation></ref><ref id="R52"><label>(52)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>Z</given-names></name><name><surname>Du</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Deng</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Peng</surname><given-names>C</given-names></name><etal/></person-group><article-title>Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors</article-title><source>Nature</source><year>2020</year><volume>582</volume><issue>7811</issue><fpage>289</fpage><lpage>293</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2223-y</pub-id></element-citation></ref><ref id="R53"><label>(53)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyata</surname><given-names>T</given-names></name><name><surname>Miyazawa</surname><given-names>S</given-names></name><name><surname>Yasunaga</surname><given-names>T</given-names></name></person-group><article-title>Two types of amino acid substitutions in protein evolution</article-title><source>J Mol Evol</source><year>1979</year><volume>12</volume><issue>3</issue><fpage>219</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1007/bf01732340</pub-id></element-citation></ref><ref id="R54"><label>(54)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ullrich</surname><given-names>S</given-names></name><name><surname>Sasi</surname><given-names>VM</given-names></name><name><surname>Mahawaththa</surname><given-names>MC</given-names></name><name><surname>Ekanayake</surname><given-names>KB</given-names></name><name><surname>Morewood</surname><given-names>R</given-names></name><name><surname>George</surname><given-names>J</given-names></name><name><surname>Shuttleworth</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Whitefield</surname><given-names>C</given-names></name><name><surname>Otting</surname><given-names>G</given-names></name><etal/></person-group><article-title>Challenges of short substrate analogues as SARS-CoV-2 main protease inhibitors</article-title><source>Bioorg Med Chem Lett</source><year>2021</year><volume>50</volume><elocation-id>128333</elocation-id><pub-id pub-id-type="doi">10.1016/j.bmcl.2021.128333</pub-id></element-citation></ref><ref id="R55"><label>(55)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeldovich</surname><given-names>KB</given-names></name><name><surname>Chen</surname><given-names>P</given-names></name><name><surname>Shakhnovich</surname><given-names>EI</given-names></name></person-group><article-title>Protein stability imposes limits on organism complexity and speed of molecular evolution</article-title><source>Pro Natl Acad Sci USA</source><year>2007</year><volume>104</volume><issue>41</issue><fpage>16152</fpage><lpage>16157</lpage><pub-id pub-id-type="doi">10.1073/pnas.0705366104</pub-id></element-citation></ref><ref id="R56"><label>(56)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wensing</surname><given-names>AMJ</given-names></name><name><surname>van Maarseveen</surname><given-names>NM</given-names></name><name><surname>Nijhuis</surname><given-names>M</given-names></name></person-group><article-title>Fifteen years of HIV protease inhibitors: raising the barrier to resistance</article-title><source>Antivir Res</source><year>2010</year><volume>85</volume><issue>1</issue><fpage>59</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2009.10.003</pub-id></element-citation></ref><ref id="R57"><label>(57)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agbowuro</surname><given-names>AA</given-names></name><name><surname>Huston</surname><given-names>WM</given-names></name><name><surname>Gamble</surname><given-names>AB</given-names></name><name><surname>Tyndall</surname><given-names>JDA</given-names></name></person-group><article-title>Proteases and protease inhibitors in infectious diseases</article-title><source>Med Res Rev</source><year>2018</year><volume>38</volume><issue>4</issue><fpage>1295</fpage><lpage>1331</lpage><pub-id pub-id-type="doi">10.1002/med.21475</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" position="float"><label>Figure 1</label><caption><title>Comparison of M<sup>pro</sup> mutations and proteolytic activities.</title><p>(a) X-ray structure of SARS-CoV-2 M<sup>pro</sup> (PDB: 6LU7)<sup><xref ref-type="bibr" rid="R52">52</xref></sup> indicating the location of mutations (red) and the catalytic dyad (purple) in the two protomers (cyan, green). (b) List of prevalent M<sup>pro</sup> mutations and their corresponding SARS-CoV-2 lineage. (c) Michaelis-Menten kinetics of SARS-CoV-2 M<sup>pro</sup> variants specifying their catalytic efficiency (<italic>k</italic>
               <sub>cat</sub>/<italic>K</italic>
               <sub>m</sub>).</p></caption><graphic xlink:href="EMS140404-f001"/></fig><fig id="F2" position="float"><label>Figure 2</label><caption><title>Inhibition of SARS-CoV-2 M<sup>pro</sup> variants.</title><p>(a) Chemical structure of the inhibitor nirmatrelvir<sup><xref ref-type="bibr" rid="R27">27</xref></sup> (b) <italic>In vitro</italic> inhibition of SARS-CoV-2 M<sup>pro</sup> variants by nirmatrelvir.</p></caption><graphic xlink:href="EMS140404-f002"/></fig></floats-group></article>